Skip to menu Skip to content Skip to footer
Professor Victoria Atkinson
Professor

Victoria Atkinson

Email: 

Overview

Background

Associate Professor Victoria Atkinson is both a Senior Medical Oncologist and a Principal Investigator for clinical trials in the adjuvant and metastatic setting at the Princess Alexandra Hospital and Greenslopes Private Hospital (in collaboration with Gallipoli Medical Research Foundation). Additionally, she is an Associate Professor with the University of Queensland, Clinical School of Medicine. Associate Professor Atkinson’s research interests are in the field of Oncology, and she has extensive experience in targeted-therapies and immunotherapies. Her main research interests are melanoma and gastro-intestinal oncology. Associate Professor Atkinson is passionate about trying to improve outcome for all patients with advanced melanoma as well as advanced gastro-intestinal cancers.

Associate Professor Atkinson has been involved in the clinical development of the current targeted and immunotherapies in melanoma over the past decade bringing these therapies into clinical practice. She has been involved in advocating for patient access to these therapies for patients in Queensland and Australia from guidelines through to reimbursement policies. These therapies have revolutionised the lives of patients and brought about the longest median overall survival for advanced melanoma. However there still remains significant work to be done in therapy resistant disease and she continues to work with therapies towards overcoming resistance.

In the past 5 years, Associate Professor Atkinson has been an Invited Speaker at 22 national and international meetings including Medical Oncology Group of Australia ASM Immunotherapy Symposium, New Zealand Society for Medical Oncology meeting and the Society for Melanoma Research congress. A/Prof Atkinson has published 82 publications, 31 oral abstracts and 65 posters. Associate Professor Atkinson is actively involved in the research supervision of her basic and advanced trainees, and resident medical officers who demonstrate interest in a project. She has supervised trainees to complete their research projects and supported 6 Australian research poster presentations, and 10 international research poster presentations.

She is passionate and motivated to continue to change practice by bringing clinically important and relevant trials to Queensland and to mentor trainees and junior consultants to continue this tradition.

Availability

Professor Victoria Atkinson is:
Available for supervision

Research interests

  • Oncology

  • Melanoma

  • Gastro-intestinal oncology

  • Patient outcomes

Works

Search Professor Victoria Atkinson’s works on UQ eSpace

111 works between 2011 and 2024

1 - 20 of 111 works

2024

Journal Article

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Bührer, Emanuel, Kicinski, Michal, Mandala, Mario, Pe, Madeline, Long, Georgina V, Atkinson, Victoria, Blank, Christian U, Haydon, Andrew, Dalle, Stéphane, Khattak, Adnan, Carlino, Matteo S, Meshcheryakov, Andrey, Sandhu, Shahneen, Puig, Susana, Schadendorf, Dirk, Jamal, Rahima, Rutkowski, Piotr, van den Eertwegh, Alfonsus J M, Coens, Corneel, Grebennik, Dmitri, Krepler, Clemens, Robert, Caroline and Eggermont, Alexander M M (2024). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 25 (9), 1202-1212. doi: 10.1016/S1470-2045(24)00338-3

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

2024

Journal Article

Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in CheckMate 238

Weber, Jeffrey, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Maria, De La Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A. and Larkin, James (2024). Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in CheckMate 238. Journal of Clinical Oncology. doi: 10.1200/JCO.23.01448

Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in CheckMate 238

2024

Journal Article

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Blank, Christian U., Lucas, Minke W., Scolyer, Richard A., van de Wiel, Bart A., Menzies, Alexander M., Lopez-Yurda, Marta, Hoeijmakers, Lotte L., Saw, Robyn P. M., Lijnsvelt, Judith M., Maher, Nigel G., Pulleman, Saskia M., Gonzalez, Maria, Acosta, Alejandro Torres, van Houdt, Winan J., Lo, Serigne N., Kuijpers, Anke M. J., Spillane, Andrew, Klop, W. Martin C., Pennington, Thomas E., Zuur, Charlotte L., Shannon, Kerwin F., Seinstra, Beatrijs A., Rawson, Robert V., Haanen, John B. A. G., Ch'ng, Sydney, Naipal, Kishan A. T., Stretch, Jonathan, van Thienen, Johannes V., Rtshiladze, Michael A. ... Long, Georgina V. (2024). Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. New England Journal of Medicine. doi: 10.1056/NEJMoa2402604

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

2024

Journal Article

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Hepner, Adriana, Versluis, Judith M., Wallace, Roslyn, Allayous, Clara, Brown, Lauren Julia, Trojaniello, Claudia, Gerard, Camille Lea, Jansen, Yanina JL, Bhave, Prachi, Neyns, Bart, Haydon, Andrew, Michielin, Olivier, Mangana, Joanna, Klein, Oliver, Shoushtari, Alexander N., Warner, Allison Betof, Ascierto, Paolo Antonio, McQuade, Jennifer Leigh, Carlino, Matteo S., Zimmer, Lisa, Lebbe, Celeste, Johnson, Douglas B., Sandhu, Shahneen, Atkinson, Victoria, Blank, Christian U., Lo, Serigne N., Long, Georgina V. and Menzies, Alexander M. (2024). The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. European Journal of Cancer, 196 113441. doi: 10.1016/j.ejca.2023.113441

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

2023

Journal Article

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Mallardo, Domenico, Woodford, Rachel, Menzies, Alexander M., Zimmer, Lisa, Williamson, Andrew, Ramelyte, Egle, Dimitriou, Florentia, Wicky, Alexandre, Wallace, Roslyn, Mallardo, Mario, Cortellini, Alessio, Budillon, Alfredo, Atkinson, Victoria, Sandhu, Shahneen, Olivier, Michielin, Dummer, Reinhard, Lorigan, Paul, Schadendorf, Dirk, Long, Georgina V., Simeone, Ester and Ascierto, Paolo A. (2023). The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. Journal of Translational Medicine, 21 (1) 753. doi: 10.1186/s12967-023-04607-4

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

2023

Journal Article

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma

Goodman, Rachel S., Di Guardo, Lorenza, Maurichi, Andrea, Kirwin, Brendan, Khattak, Adnan, Vanella, Vito, Lee, Joanna, Lawless, Aleigha, Czapla, Juliane, Spagnoletti, Andrea, Ambrosini, Margherita, Livingstone, Elisabeth, Long, Georgina V., Sullivan, Ryan J., Carlino, Matteo S., Atkinson, Victoria, Trojanello, Claudia, Ascierto, Paolo A., Schadendorf, Dirk, Warburton, Lydia, Menzies, Alexander M., Santinami, Mario and Johnson, Douglas B. (2023). Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal of Cancer, 194 113354, 113354. doi: 10.1016/j.ejca.2023.113354

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma

2023

Journal Article

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Arance, Ana, de la Cruz-Merino, Luis, Petrella, Teresa M., Jamal, Rahima, Ny, Lars, Carneiro, Ana, Berrocal, Alfonso, Márquez-Rodas, Ivan, Spreafico, Anna, Atkinson, Victoria, Costa Svedman, Fernanda, Mant, Andrew, Khattak, Muhammad A., Mihalcioiu, Catalin, Jang, Sekwon, Cowey, C Lance, Smith, Alan D., Hawk, Natalyn, Chen, Ke, Diede, Scott J., Krepler, Clemens and Long, Georgina V. (2023). Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. Journal of Clinical Oncology, 41 (1), 75-85. doi: 10.1200/JCO.22.00221

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

2023

Conference Publication

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial

Khattak, Adnan, Weber, Jeffrey S., Meniawy, Tarek, Taylor, Matthew H., Ansstas, George, Kim, Kevin B., McKean, Meredith, Long, Georgina V., Sullivan, Ryan J., Faries, Mark B., Tran, Thuy, Cowey, Charles Lance, Medina, Theresa Michelle, Segar, Jennifer Margaret, Atkinson, Victoria, Gibney, Geoffrey Thomas, Luke, Jason J., Buchbinder, Elizabeth Iannotti, Meehan, Robert S., Carlino, Matteo S. and on behalf of Moderna Author's Group (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2023.41.17_suppl.LBA9503

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial

2023

Journal Article

Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy

Thompson, Jake R., Lai-Kwon, Julia, Morton, Rachael L., Guminski, Alexander D., Gonzalez, Maria, Atkinson, Victoria, Sandhu, Shahneen, Brown, Michael P., Menzies, Alexander M., Mcarthur, Grant A., Lo, Serigne N., Long, Georgina V. and Bartula, Iris (2023). Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Immunotherapy, 15 (8), 593-610. doi: 10.2217/imt-2022-0262

Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy

2023

Journal Article

Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Weber, Jeffrey S., Schadendorf, Dirk, Del Vecchio, Michele, Larkin, James, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Brown, Michael P., Rutkowski, Piotr, Haydon, Andrew, Grob, Jean-Jacques, Schachter, Jacob, Queirolo, Paola, De La Cruz-Merino, Luis, Van Der Westhuizen, Andre, Menzies, Alexander M. ... Long, Georgina V. (2023). Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of Clinical Oncology, 41 (3), 517-527. doi: 10.1200/JCO.22.00533

Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

2023

Journal Article

Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy

Sandhu, Shahneen, Atkinson, Victoria, Cao, Maria González, Medina, Theresa, Rivas, Ainara Soria, Menzies, Alexander M., Caro, Ivor, Roberts, Louise, Song, Yuyao, Yan, Yibing, Guo, Yu, Xue, Cloris and Long, Georgina V. (2023). Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy. European Journal of Cancer, 178, 180-190. doi: 10.1016/j.ejca.2022.10.019

Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy

2023

Journal Article

Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey

Thompson, Jake R., Fu, Hong, Saw, Robyn P. M., Sherman, Kerry A., Beedle, Victoria, Atkinson, Victoria, Boyle, Frances, O’Sullivan, Niamh A., Martin, Linda K. and Bartula, Iris (2023). Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey. Quality of Life Research, 32 (12), 3531-3545. doi: 10.1007/s11136-023-03492-0

Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey

2023

Journal Article

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes

Lee, Joanna, Ahmed, Tasnia, Maurichi, Andrea, Di Guardo, Lorenzo, Stagno, Anna M., Warburton, Lydia, Taylor, Amelia. M., Livingstone, Elisabeth, Rehman, Saba, Khattak, Adnan, Kahler, Katharina C., Vanella, Vito, Atkinson, Victoria, Millward, Michael, Schadendorf, Dirk, Johnson, Douglas B., Ascierto, Paolo A., Hauschild, Axel, Lo, Serigne N., Long, Georgina V., Menzies, Alexander M. and Carlino, Matteo S. (2023). BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. European Journal of Cancer, 179, 87-97. doi: 10.1016/j.ejca.2022.11.009

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes

2022

Journal Article

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study

Dimitriou, F., Namikawa, K., Reijers, I. L.M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C. J., Zaman, F., Haydon, A., Carvajal, R. D., Hamid, O., Dummer, R., Hauschild, A. ... Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33 (9), 968-980. doi: 10.1016/j.annonc.2022.06.004

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study

2022

Journal Article

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

Larkin, James, Weber, Jeffrey, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Marie, Middleton, Mark R., De la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A. and Mandalá, Mario (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European Journal of Cancer, 173, 285-296. doi: 10.1016/j.ejca.2022.06.041

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

2022

Conference Publication

Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma

Aoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357

Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma

2022

Journal Article

In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case series

Sanjida, Saira, Betz-Stablein, Brigid, Atkinson, Victoria, Janda, Monika, Barsoum, Ramez, Edwards, Harrison Aljian, Chiu, Frank, Tran, My Co, Soyer, H. Peter and Schaider, Helmut (2022). In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case series. Cancers, 14 (11) 2801, 2801. doi: 10.3390/cancers14112801

In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case series

2022

Conference Publication

Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer

Iqbal, Samreen, Atkinson, Victoria, Arneil, Melissa, Andelkovic, Vladimir and Roberts, Kate Elizabeth (2022). Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer. 2022 ASCO Annual Meeting, Chicago, IL United States, 3-7 June 2022. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2022.40.16_suppl.e16033

Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer

2022

Journal Article

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy

Ng, Gary, Xu, Wen and Atkinson, Victoria (2022). Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. Current Oncology Reports, 24 (10), 1273-1280. doi: 10.1007/s11912-022-01288-y

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy

2022

Journal Article

Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes

Shanker, Mihir D., Garimall, Sidyarth, Gatt, Nick, Foley, Heath, Crowley, Samuel, Le Cornu, Emma, Muscat, Kendall, Soon, Wei, Atkinson, Victoria, Xu, Wen, Watkins, Trevor, Huo, Michael, Foote, Matthew C. and Pinkham, Mark B. (2022). Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of Medical Imaging and Radiation Oncology, 66 (4), 536-545. doi: 10.1111/1754-9485.13403

Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes

Funding

Current funding

  • 2023 - 2026
    Assessment of tumour phenotype for precision medicine in oesophageal cancer via deep learning analysis of medical images
    CCQ Accelerating Collaborative Cancer Research
    Open grant
  • 2021 - 2025
    Novel predictive disease modelling using liquid biopsies to improve outcomes in melanoma (MRFF Genomics Health Futures Mission grant led by the University of Melbourne)
    University of Melbourne
    Open grant
  • 2020 - 2025
    Circulating tumour DNA guidEd Therapy for stage IIB/C BRAF mutant positive mElanoma after surgiCal resecTION (DETECTION) (MRFF ICTC led by University of Melbourne)
    University of Melbourne
    Open grant
  • 2018 - 2025
    A Randomised Phase III Study of the duration of the Anti-PD1 - therapy in metastatic melanoma (STOP-GAP)
    NHMRC Project Grant
    Open grant

Past funding

  • 2020 - 2021
    Cancer Evolution Biobank
    PA Research Foundation
    Open grant

Supervision

Availability

Professor Victoria Atkinson is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Professor Victoria Atkinson's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au